Disitamab Vedotin (RC48) in Combination With AK104 (PD-1/CTLA-4 Bispecific) and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer: a Single-arm, Phase II, Multicenter Study (DAB OCC Study)
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Bevacizumab (Primary) ; Cadonilimab (Primary) ; Disitamab vedotin (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms DAB OCC Study
Most Recent Events
- 12 Aug 2024 New trial record